ArticleBreast cancer (Dove Medical Press)2025
Dual Receptor Targeting Ensures Uptake and Anticancer Efficacy of Low-Density Lipoprotein-Docosahexaenoic Acid Nanoparticles Across Breast Cancer Cell Subtypes.
Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Introduction: Aberrant acquisition of lipoprotein cholesterol remains a hallmark feature of breast cancer biology. Low- and high-density lipoprotein receptors (LDLR and scavenger receptor class B type 1 (SR-B1)) are often upregulated to facilitate the tumor cells' high demand for cholesterol. To date, few attempts have been made to therapeutically exploit the high activity of lipoprotein receptors in breast cancer cells. Methods: In the present study, we examined the utility of engineered low-density lipoprotein nanoparticles to deliver the natural anticancer omega-3 fatty acid docosahexaenoic acid (LDL-DHA) across a panel of breast cancer cells. Results: Our data showed that LDL-DHA nanoparticles were avidly taken up (K Conclusion: In summary, our studies have shown that malignant cell dependence upon cholesterol acquisition can be exploited for lipoprotein-based drug delivery to breast cancer cells. Furthermore, the capacity of LDL nanoparticles to target both LDLR and SR-B1 ensures this as an efficient drug delivery platform against breast cancer cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.